Enhancement of in-vitro anti-oral cancer activities of silymarin using dispersion of nanostructured lipid carrier in mucoadhesive in-situ gel

Shete, Meghanath B.; Deshpande, Ashwini; Shende, Pravin

doi:10.1016/j.ijpharm.2023.122860

Cited by 6 publications

(2 citation statements)

References 58 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Had a higher inhibitory effect on human KB OC cells. [ 165 ] QRC and piperine QRC and piperine-enriched NLCs Cell cycle arrest effect of QRC and piperine Dual drug-loaded NLCs were more effective than the pure drug solution. Improved apoptosis in NLCs.…”

Section: Nano-ddss In Oc Therapymentioning

confidence: 99%

Nano-Drug Delivery Systems in Oral Cancer Therapy: Recent Developments and Prospective

Zhang,

Wu,

et al. 2023

Pharmaceutics

View full text Add to dashboard Cite

Oral cancer (OC), characterized by malignant tumors in the mouth, is one of the most prevalent malignancies worldwide. Chemotherapy is a commonly used treatment for OC; however, it often leads to severe side effects on human bodies. In recent years, nanotechnology has emerged as a promising solution for managing OC using nanomaterials and nanoparticles (NPs). Nano-drug delivery systems (nano-DDSs) that employ various NPs as nanocarriers have been extensively developed to enhance current OC therapies by achieving controlled drug release and targeted drug delivery. Through searching and analyzing relevant research literature, it was found that certain nano-DDSs can improve the therapeutic effect of drugs by enhancing drug accumulation in tumor tissues. Furthermore, they can achieve targeted delivery and controlled release of drugs through adjustments in particle size, surface functionalization, and drug encapsulation technology of nano-DDSs. The application of nano-DDSs provides a new tool and strategy for OC therapy, offering personalized treatment options for OC patients by enhancing drug delivery, reducing toxic side effects, and improving therapeutic outcomes. However, the use of nano-DDSs in OC therapy still faces challenges such as toxicity, precise targeting, biodegradability, and satisfying drug-release kinetics. Overall, this review evaluates the potential and limitations of different nano-DDSs in OC therapy, focusing on their components, mechanisms of action, and laboratory therapeutic effects, aiming to provide insights into understanding, designing, and developing more effective and safer nano-DDSs. Future studies should focus on addressing these issues to further advance the application and development of nano-DDSs in OC therapy.

show abstract

Section: Nano-ddss In Oc Therapymentioning

confidence: 99%

Nano-Drug Delivery Systems in Oral Cancer Therapy: Recent Developments and Prospective

Zhang,

Wu,

et al. 2023

Pharmaceutics

View full text Add to dashboard Cite

show abstract

“…A dialysis membrane with 12-14 kDa MWCO (Spectra/por ® Spectrum Laboratories Inc. Rancho Dominguez, Berkeley, CA, USA) was utilized for the study and was previously soaked in SSF (pH 6.8) overnight. Samples of NLCs (containing 2 mg of paliperidone) were mixed in SSF and kept inside the membrane and immersed in a beaker containing 100 mL of receiver fluid (SSF with 0.5% Tween 80; pH 6.8; solubility 0.82 ± 0.11 mg/mL) to maintain the sink condition [35]. The complete apparatus was placed on a water bath adjusted to maintain a temperature of 37 ± 0.5 • C, and the receptor medium was agitated at 50 rpm.…”

Section: Entrapment Efficiency (Ee) and Drug Loadingmentioning

confidence: 99%

Design, Development, Evaluation, and In Vivo Performance of Buccal Films Embedded with Paliperidone-Loaded Nanostructured Lipid Carriers

AlMulhim,

Nair,

Aldhubiab

et al. 2023

Pharmaceutics

View full text Add to dashboard Cite

The therapeutic effectiveness of paliperidone in the treatment of schizophrenia has been limited by its poor oral bioavailability; hence, an alternative route could be appropriate. This study investigates the feasibility of developing a buccal film impregnated with paliperidone-loaded nanostructured lipid carriers (NLCs) and assesses the potential to enhance its bioavailability. Box–Behnken-based design optimization of NLCs was performed by examining the particles’ physical characteristics. The polymeric film was used to load optimized NLCs, which were then assessed for their pharmaceutical properties, permeability, and pharmacokinetics. The optimization outcomes indicated that selected formulation variables had a considerable (p < 0.05) impact on responses such as particle size, entrapment efficiency, and % drug release. Desired characteristics such as a negative charge, higher entrapment efficiency, and nanoparticles with ideal size distribution were shown by optimized NLC dispersions. The developed film demonstrated excellent physico-mechanical properties, appropriate texture, good drug excipient compatibility (chemically stable formulation), and amorphous drug nature. A sustained Weibull model drug release (p < 0.0005) and superior flux (~5-fold higher, p < 0.005) were seen in NLC-loaded film compared to plain-drug-loaded film. The pharmacokinetics profile in rabbits supports the goal of buccal therapy as evidenced by significantly higher AUC0–12 (p < 0.0001) and greater relative bioavailability (236%) than the control. These results support the conclusion that paliperidone-loaded NLC buccal film has the potential to be an alternate therapy for its effective administration in the treatment of schizophrenia.

show abstract

QbD-driven development of phospholipid-embedded lipidic nanocarriers of raloxifene: extensive in vitro and in vivo evaluation studies

Pant,

Sharma,

Saini

et al. 2023

Drug Deliv. and Transl. Res.

View full text Add to dashboard Cite

Enhancement of in-vitro anti-oral cancer activities of silymarin using dispersion of nanostructured lipid carrier in mucoadhesive in-situ gel

Cited by 6 publications

References 58 publications

Nano-Drug Delivery Systems in Oral Cancer Therapy: Recent Developments and Prospective

Nano-Drug Delivery Systems in Oral Cancer Therapy: Recent Developments and Prospective

Design, Development, Evaluation, and In Vivo Performance of Buccal Films Embedded with Paliperidone-Loaded Nanostructured Lipid Carriers

QbD-driven development of phospholipid-embedded lipidic nanocarriers of raloxifene: extensive in vitro and in vivo evaluation studies

Contact Info

Product

Resources

About